Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Jose Saro

Christian Klein

Pablo Umana

Pablo Umaña

Marina Bacac

Johannes Sam

Stefan Evers

Pavel Pisa

Eva Rossmann

Sara Colombetti

The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent. The invention further relates to methods of treating a disease, particularly a B-cell proliferative disorder, and methods for reduction of adverse effects in response to the administration of a therapeutic agent, particularly a T-cell activating therapeutic agent.

Treatment method

The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.

Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies

Growing community of inventors

Schlieren, Switzerland

Jose Saro